Skip to main content
Shanghai Hile Bio-Technology Co.,Ltd logo

Shanghai Hile Bio-Technology Co.,Ltd — Investor Relations & Filings

Ticker · 603718 ISIN · CNE1000022T4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,480 across all filing types
Latest filing 2025-11-30 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603718

About Shanghai Hile Bio-Technology Co.,Ltd

http://www.hile-bio.com/

Shanghai Hile Bio-Technology Co., Ltd. specializes in the research, development, production, and distribution of veterinary biological products. The company focuses on providing comprehensive health solutions for the livestock and poultry sectors. Its core product portfolio includes a wide range of vaccines targeting major animal diseases, such as swine fever, porcine reproductive and respiratory syndrome (PRRS), foot-and-mouth disease, and various avian influenza strains. Utilizing advanced biotechnology and large-scale manufacturing processes, the company operates high-standard production facilities compliant with Good Manufacturing Practice (GMP) requirements. Hile Bio-Technology emphasizes innovation through its dedicated research and development centers, aiming to enhance animal disease prevention and control. The company serves large-scale farming enterprises and veterinary service providers, maintaining a significant presence in the animal health sector through its commitment to product quality and technical support.

Recent filings

Filing Released Lang Actions
海利生物关于收购控股子公司少数股东权益暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Shanghai Haili Biological Technology Co., Ltd. regarding the acquisition of minority interests in a controlled subsidiary and related party transactions. It includes extensive information about the transaction terms, asset valuation, financial data of the subsidiary, board and independent director approvals, and risk disclosures. The document is not a full annual or interim report but a specific corporate announcement about a capital transaction involving acquisition of shares and related party dealings. It is not a simple notice or a report publication announcement but a substantive disclosure about a capital/financing update and related party transaction. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-11-30 Chinese
海利生物关于公司使用闲置自有资金委托理财的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shanghai Haili Biotechnology Co., Ltd. regarding the company's use of idle self-owned funds for entrusted financial management. It details the investment amount, types of financial products, risk analysis, internal controls, and the impact on the company. The document includes a summary of recent financial indicators but does not contain comprehensive financial statements or detailed financial analysis. It is a formal announcement about financing activities related to the company's capital management rather than a full financial report or earnings release. The document length is about 3,000 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2025-11-30 Chinese
上海市通力律师事务所关于上海海利生物技术股份有限公司2025年第二次临时股东会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, and results of a specific shareholders' meeting (the 2025 second extraordinary general meeting) of Shanghai Haili Biotechnology Co., Ltd. It details the legality of the meeting's call, attendance, voting procedures, and results. It does not contain financial statements or detailed financial data, nor is it a report of financial performance or management discussion. It is not a notice of voting results per se, but a legal opinion on the meeting's procedural compliance and validity of the voting process. Given the nature of the document as a legal opinion on a shareholders' meeting, it fits best under Regulatory Filings (RNS), which covers compliance documents and miscellaneous filings that do not fit other categories. The document length is short (3306 characters), and it is not an announcement of a report but a standalone legal opinion letter.
2025-11-14 Chinese
海利生物2025年第二次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2025 second extraordinary shareholders meeting of Shanghai Haili Biotechnology Co., Ltd. It details the meeting date, attendance, voting results, and legal witness statements. The content focuses on the announcement of voting results for a specific agenda item (appointment of the accounting firm for 2025). The document is relatively short (1611 characters) and does not contain financial statements or detailed financial analysis. It is not a full report but an official disclosure of shareholder meeting voting outcomes. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-11-14 Chinese
海利生物2025年第二次临时股东会会议资料
AGM Information Classification · 95% confidence The document is titled as meeting materials for the 2025 second extraordinary shareholders meeting of Shanghai Haili Biotechnology Co., Ltd. It includes detailed agenda items, voting procedures, and a specific proposal regarding the appointment of the company's auditor for the 2025 fiscal year. The content focuses on the appointment of the accounting firm for audit services, including background information on the firm, personnel, and reasons for the change. This is typical of materials prepared for a shareholders meeting to inform and solicit votes on corporate governance matters. The document is not a full audit report, annual report, or financial statement, but rather meeting materials related to a shareholders meeting. Given the nature and content, this fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting or other shareholders meetings. The document length is under 5,000 characters, but it contains substantive meeting agenda and proposal details, not just an announcement of a report publication. Therefore, it is not an RPA or RNS. Hence, the classification is AGM-R with high confidence.
2025-11-06 Chinese
海利生物关于公司2023年限制性股票与股票期权激励计划限制性股票第二个解除限售期解除限售条件未成就暨调整回购价格及行权价格并回购注销部分限制性股票与部分股票期权注销的公告
Transaction in Own Shares Classification · 95% confidence The document is an official announcement from Shanghai Haili Biotechnology Co., Ltd. regarding the 2023 restricted stock and stock option incentive plan. It details the failure to meet the conditions for the second restricted stock release period, adjustments to repurchase and exercise prices, and the repurchase and cancellation of certain restricted stocks and stock options. The content focuses on stock incentive plan adjustments, repurchase, and cancellation, which are related to share transactions by the company involving its own shares. There is no indication that this is a full financial report, earnings release, or regulatory certification. The document is not a report publication announcement but a detailed announcement of share repurchase and cancellation activities under the incentive plan. Therefore, the most appropriate classification is Transaction in Own Shares (POS).
2025-10-29 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.